PCI Biotech Holding ASA (OSL:PCIB) Change In Receivables : kr0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Change In Receivables?

PCI Biotech Holding ASA's change in receivables for the quarter that ended in Dec. 2024 was kr0.00 Mil. It means PCI Biotech Holding ASA's Accounts Receivable stayed the same from Jun. 2024 to Dec. 2024 .

PCI Biotech Holding ASA's change in receivables for the fiscal year that ended in Dec. 2024 was kr-1.27 Mil. It means PCI Biotech Holding ASA's Accounts Receivable increased by kr1.27 Mil from Dec. 2023 to Dec. 2024 .

PCI Biotech Holding ASA's Accounts Receivable for the quarter that ended in Dec. 2024 was kr0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. PCI Biotech Holding ASA's liquidation value for the six months ended in Dec. 2024 was kr18.93 Mil.

PCI Biotech Holding ASA Change In Receivables Historical Data

The historical data trend for PCI Biotech Holding ASA's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Change In Receivables Chart

PCI Biotech Holding ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

1.48

0.96

6.04

3.59

-1.27

PCI Biotech Holding ASA Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

PCI Biotech Holding ASA Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr0.00 Mil.

PCI Biotech Holding ASA (OSL:PCIB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

PCI Biotech Holding ASA's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, PCI Biotech Holding ASA's accounts receivable are only considered to be worth 75% of book value:

PCI Biotech Holding ASA's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	26.693	-	7.762	+	0.75 * 0	+	0.5 * 0
=	18.93

PCI Biotech Holding ASA Change In Receivables Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (OSL:PCIB) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

0JGL:UK 4QG:Germany

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines